Concept sbir - t-cell receptors for treating pediatric acute myeloid leukemia
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91024C00001
- Awardee
-
Vcreate, Inc. UEI TDGANH2K4J93
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $355,000
Award facts
- Opportunity
-
- National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program – Fiscal Year 2024 Pre-Solicitation · 75N91023R00034 · Posted Feb 27, 2023
- Contract value 100% obligated
- $355,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 52 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Menlo Park, CA 94025, USA
- Research
- STTR Phase I
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $355,000 |
About this award
This is a $355,000 firm fixed price definitive contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health, to Vcreate, Inc., a minority-owned, self-certified small disadvantaged business. The contract is a Phase I Small Business Technology Transfer (STTR) award that supports the development of T-cell receptors for treating pediatric acute myeloid leukemia.
The contract was set aside for small businesses and aims to demonstrate technical feasibility and proof-of-concept for this innovative cancer treatment approach. Vcreate, Inc. is conducting the research in West Menlo Park, California, with a scheduled completion date of February 2025. This award highlights Vcreate's capability to secure competitive federal contracts in the biomedical research sector, particularly in addressing critical needs in pediatric cancer therapeutics.
Quick answers
Who was awarded contract 75N91024C00001?
75N91024C00001 was awarded to Vcreate, Inc. by National Cancer Institute (National Institutes of Health) on February 15, 2024.
How much is contract 75N91024C00001 worth?
The government has obligated $355,000 on 75N91024C00001.
Was contract 75N91024C00001 competed?
The extent of competition for 75N91024C00001 was full and open competition after exclusion of sources. The government received 52 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award